Driven by the potential to treat the root cause ofdiseases, including rare clinical conditions and those that were previouslydeemed incurable, the gene therapies pipeline is growing, and the marketanticipated to witness substantial growth, till 2030
Roots Analysis has announced the addition of “Gene Therapy Market (4th Edition), 2020-2030” report toits list of offerings.
Successof approved gene therapies has resulted in a surge in interest of biopharmaceuticaldevelopers in this rapidly evolving domain. Presently, the ability of genetherapies to treat diverse disease indications is considered among the mostprominent drivers of this market. In addition, promising clinical results ofpipeline candidates are anticipated to draw in more investments to supportproduct development initiatives.
To order this 720+page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
Around 800 gene therapies are currently being developedacross different stages
Apartfrom 10 approved products, most of the aforementioned therapies (65%) are inthe early stages of development (discovery / preclinical), while the rest arebeing evaluated in clinical trials. It is worth mentioning that more than 40%of clinical stage candidates are intended for the treatment of oncologicaldisorders.
Over 65% of innovator companies focused on gene therapydevelopment, are based in North America
Interestingly,more than 75 players based in the same region, are start-ups, while over 35 aremid-sized players, and 10 are large and very large firms. Since the majority ofgene therapy developers are headquartered in the US, it is considered a key R&Dhub for such advanced therapy medicinal products.
There are 400+ registered gene therapy focused clinicaltrials, worldwide
Clinicalresearch activity, in terms of number of trials registered, is reported to haveincreased at a CAGR of 12% during the period 2015-2020. Of the total number oftrials, close to 25% have already been completed, and 35% claim to be activelyrecruiting.
USD 25.4 billion has been invested by both private andpublic investors, since 2015
Sofar, a significant proportion of the capital raised has been through secondaryofferings (USD 12.9 billion). On the other hand, around USD 5 billion wasinvested by venture capital investors, representing 20% of the total amount.
Close to 20,000 patents have been filed / published relatedto gene therapies, since 2016
Around30% of the total number of applications were related to gene editing-basedtherapies, while the remaining were associated with gene therapies. Further,majority of the patent assignees were industry players, however, the contributionof non-industry players in the overall patent filing activity has increasedconsiderably (CAGR of 16%), over the past few years.
There have been several mergers and acquisitions in thismarket during the period 2015-2019
Infact, M&A activity is reported to have increased at a CAGR of more than40%. Key drivers of the acquisitions mentioned in the report include,therapeutic area expansion, access to a novel technology / platform, drug classconsolidation and drug class expansion.
To request a sample copy / brochure of this report, pleasevisit this -https://www.rootsanalysis.com/reports/268/request-sample.html
The report featuresinputs from eminent industry stakeholders, according to whom, gene therapiesexhibit the potential to become a promising alternative for the treatment ofgenetic disorders. The report includes detailed transcripts of discussions heldwith the following experts:
§ AdamRogers (CEO, Hemera Biosciences)
§ AlHawkins (CEO, Milo Biotechnology)
§ BuelDan Rodgers (Founder & CEO, AAVogen)
§ ChristopherReinhard (CEO & Chairman, Gene Therapeutics (previously known as CardiumTherapeutics))
§ MichaelTriplett (ex-CEO, Myonexus Therapeutics)
§ RobertJan Lamers (ex-CEO, Arthrogen)
§ RyoKubota (CEO, Chairman & President, Acucela)
§ TomWilton (ex-CBO, LogicBio Therapeutics)
§ JeffreyHung (CCO, Vigene Biosciences)
§ CedricSzpirer (Executive & Scientific Director, Delphi Genetics)
§ MarcoSchmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager,PlasmidFactory)
§ MollyCameron (Corporate Communications Manager, Orchard Therapeutics)
The research includesbrief profiles of key players (listed below) engaged in the developmentof gene therapies; each profile features an overview of the therapy, currentdevelopment status, clinical trials and its results (if available), targetindication, route of administration, and recent developments (if available).
§ Abeona Therapeutics
§ Advantagene
§ Biogen
§ bluebird bio
§ Castle Creek Biosciences
§ CG Oncology
§ FerGene
§ Freeline Therapeutics
§ Gradalis
§ Helixmith
§ Inovio Pharmaceuticals
§ Kolon TissueGene
§ Krystal Biotech
§ Lysogene
§ Neurophth Therapeutics
§ OncoSec Immunotherapies
§ Orchard Therapeutics
§ Pfizer
§ Sangamo Therapeutics
§ Spark Therapeutics
§ uniQure Biopharma
§ VBLTherapeutics
For additional details, pleasevisit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com
You may also beinterested in the following titles:
1. ViralVectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4thEdition), 2021-2030
2. GlobalT-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3. OncolyticVirus Therapy Market: Pipeline Review, Developer Landscape and CompetitiveInsights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
